Ocular Therapeutix Inc
ocutx.comOcular Therapeutix (NASDAQ: OCUL) is a biopharmaceutical company that develops and commercializes drug products for ophthalmic diseases and conditions. Revenue comes primarily from product sales of DEXTENZA, an FDA-approved intracanalicular insert for treatment of ocular pain following ophthalmic surgery (approved November 2018) and ocular itching associated with allergic conjunctivitis, distributed through a limited number of specialty distributors in the United States. The company also generates licensing revenue through its AffaMed License Agreement, which included a $12.0 million upfront payment and eligibility for up to $91.0 million in aggregate milestone and clinical development support payments, plus tiered royalties ranging from the low-teens to low-twenty percent range on future product sales. AXPAXLI is the company's primary pipeline candidate as of the 10-K filed 2026-02-05. ReSure Sealant, a hydrogel corneal sealant commercialized in the United States starting in 2014, had production suspended in 2021 and its marketing authorization withdrawn in 2025.
Products & Services
DEXTENZA (dexamethasone intracanalicular insert): approved for post-surgical ocular pain and ocular itching from allergic conjunctivitis. AXPAXLI: pipeline candidate in clinical development. OTX-TIC: licensed to AffaMed for reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension. ReSure Sealant: hydrogel corneal sealant, production suspended 2021, marketing authorization withdrawn 2025.
Revenue Model
Transactional product revenue from U.S. sales of DEXTENZA through specialty distributors, supplemented by licensing fees, milestone payments, clinical development support payments, and tiered royalties from the AffaMed License Agreement covering Greater China rights to DEXTENZA and OTX-TIC.
Customers & Markets
Ophthalmology end market, specifically patients undergoing ophthalmic surgery and patients with allergic conjunctivitis. Immediate customers are a limited number of specialty distributors in the United States. End users are ophthalmic surgeons and their patients. Medicare and Medicaid are material payers given the surgical setting.
Geographic Exposure
United States (primary commercial market for DEXTENZA). Greater China rights licensed to AffaMed. European regulatory environment monitored but no commercial operations described in the filing excerpts.
Financial Snapshot
Loading...
